Playtika Slips Again as Investors Look for a Spark

Playtika Slips Again as Investors Look for a Spark

June 5, 2026

NEW YORK, June 4, 2026, 18:01 EDT

Playtika Holding Corp. slipped again Thursday, with the mobile-games group under pressure while most of the wider U.S. market was steadier. Shares on the Nasdaq last changed hands at $3.15, down 5 cents, with around 984,000 shares moved.

Playtika is betting that strength in newer games and higher direct-to-consumer sales will balance out the slumps in its older franchises. Direct-to-consumer, or DTC, is when players pay straight through the company’s own channel, instead of mostly using app stores.

The move wasn’t just about the market. The S&P 500 added 0.41% and the Dow climbed 1.73% Thursday. The Nasdaq Composite edged down 0.09% as chip names put pressure on the tech index.

Playtika trailed some small-cap peers, with its $1.2 billion market cap putting it in that group. The Russell 2000 index climbed 1.4% on Thursday, getting a boost from falling oil prices and lower bond yields, according to AP.

No new earnings came out Thursday. The most recent update on Playtika’s investor-relations page was from June 2, announcing Solitaire Grand Harvest joined the Green Game Jam. The event runs June 2-9 and backs coral reef restoration. Roi Glazer, Solitaire Grand Harvest general manager, said the project proved “gaming can create a genuine real-world impact.” Playtika

Playtika’s main issue right now is financial, not about its environmental branding. The company posted first-quarter revenue of $744.7 million, up 5.5% from a year ago. DTC platforms revenue came in at $291.8 million, jumping 62.8%. Net loss was $57.5 million. Adjusted EBITDA was $125.2 million, down 25.2% from the prior year. Adjusted EBITDA removes interest, taxes, depreciation, amortization, and company-specific items.

Chief Executive Robert Antokol said the quarter was a “strong start to 2026.” Chief Financial Officer Tae Lee called results “ahead of our prior expectations.” Lee said SuperPlay is tracking above plan and said he expects investment spending to normalize before year-end. Playtika

Playtika’s higher 2026 revenue forecast—now $2.75 billion to $2.85 billion—and new adjusted EBITDA view of $750 million to $790 million didn’t settle all investor worries. The first-quarter loss and a lower EBITDA margin are raising questions about how much Playtika will have to spend to keep growth going. Investors aren’t seeing the guidance bump as an all-clear.

Gaming stocks were uneven, with no clear direction for the sector. Take-Two Interactive ended down 2.96% on Wednesday. Electronic Arts edged up 0.31%. Playtika shares lost 5.03%, MarketWatch data show.

Analyst caution on Playtika is sticking around, but not getting worse. Roth MKM’s Eric Handler stuck with his Hold call on May 27 and bumped his price target up to $3.50 from $3.00, according to StockAnalysis via TipRanks.

The downside for Playtika is clear. The company has flagged risks like heavy dependence on Apple’s App Store and Google Play, the fact it relies on a handful of games and spending players, tough competition, geopolitical issues in Israel and Ukraine, and the task of finding new funding or refinancing a $550 million revolving credit line that matures in March 2027.

Looking to the week ahead, trading will pivot on price moves and whether investors seem ready to move on from the first-quarter loss. With no new company filing or shift in engagement showing up, the shares could keep moving more like a low-priced, event-driven stock than a growth name.

Stock Market Today

  • Cochlear Shares Plunge 65% Amid Challenges but Long-Term Prospects Remain Strong
    June 4, 2026, 6:19 PM EDT. Shares of Cochlear Ltd (ASX: COH) have fallen 65% over the past year following a severe April guidance downgrade. The company faces headwinds including fewer surgeries, slower hearing aid referrals, and Middle East sales disruptions. Despite market concerns, Cochlear maintains a 50% global implant market share with a vast untapped market representing over six million patients. CEO Dig Howitt cites growing clinical demand and links implants to lower dementia rates. Temporary setbacks mirror past patterns seen in healthcare stocks like ResMed, suggesting potential recovery. Broker targets range widely, with Jarden at A$169 and consensus near A$232, signaling significant upside for long-term holders amid volatility.